Melphalan · Evomela, Ivra

What is Melphalan?

Melphalan is a phenylalanine derivative of nitrogen mustard with antineoplastic activity. It alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. It is studied in recurrent and refractory B-cell lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Evomela, Ivra, CB-3025, WR-19813, Alanine Nitrogen Mustard, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin

Drug type

Small molecule

Mechanism

Cytotoxic

Pathways

DNA alkylation, DNA inter-strand cross-linkages, DNA synthesis inhibition, RNA synthesis inhibition

Therapy area

Oncology

Developer

Acrotech Biopharma

In trials of

ADCT, TCRT

FDA status

Approved as Evomela, Ivra (March 10, 2016), NDA207155

UNII

Q41OR9510P

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell LymphomaLymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT00968760

Updated Oct 3, 2026.